Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053198
Filing Date
2024-05-06
Accepted
2024-05-06 07:06:23
Documents
89
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q omga-20240331.htm   iXBRL 10-Q 2136300
2 EX-10.1 omga-ex10_1.htm EX-10.1 54916
3 EX-31.1 omga-ex31_1.htm EX-31.1 15525
4 EX-31.2 omga-ex31_2.htm EX-31.2 15294
5 EX-32.1 omga-ex32_1.htm EX-32.1 8924
6 EX-32.2 omga-ex32_2.htm EX-32.2 8692
7 GRAPHIC img33839852_0.jpg GRAPHIC 5014
8 GRAPHIC img33839852_1.jpg GRAPHIC 3735
9 GRAPHIC img33839852_2.jpg GRAPHIC 3975
10 GRAPHIC img33839852_3.jpg GRAPHIC 4186
11 GRAPHIC img33839852_4.jpg GRAPHIC 4222
  Complete submission text file 0000950170-24-053198.txt   8987282

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT omga-20240331.xsd EX-101.SCH 1518226
93 EXTRACTED XBRL INSTANCE DOCUMENT omga-20240331_htm.xml XML 1223529
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40657 | Film No.: 24915523
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)